Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan

Published:2024-03 Issue: Volume:40 Page:118-126
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Maeda Tomomi,Moriwaki Kensuke,Morimoto Kosuke,Mo Xiuting,Yoshioka Takashi,Goto Rei,Shimozuma Kojiro

Funder

National Institutes of Health

Publisher

Elsevier BV

Reference14 articles.

1. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma;Motzer;Cancer,2022

2. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma;Wu;J Immunother Cancer,2018

3. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis;Wan;JAMA Oncol,2019

4. A cost-effectiveness analysis of nivolumab and ipilimumab versus sunitinib in first-line intermediate- to poor-risk advanced renal cell carcinoma;Reinhorn;Oncologist,2019

5. Nivolumab plus ipilimumab versus sunitinib in Advanced Renal-Cell Carcinoma;Motzer;N Engl J Med,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP